biostudies-literatureUnknown46(5)Pan H<h4>Background</h4>Ginsenoside Rg3 and gemcitabine have mutual enhancing antitumor effects. However, the underlying mechanisms are not clear. This study explored the influence of ginsenoside Rg3 on Zinc finger protein 91 homolog (ZFP91) expression in pancreatic adenocarcinoma (PAAD) and their regulatory mechanisms on gemcitabine sensitivity.<h4>Methods</h4>RNA-seq and survival data from The Cancer Genome Atlas (TCGA)-PAAD and Genotype-Tissue Expression (GTEx) were used for <i>in-silicon</i> analysis. PANC-1, BxPC-3, and PANC-1 gemcitabine-resistant (PANC-1/GR) cells were used for <i>in vitro</i> analysis. PANC-1 derived tumor xenograft nude mice model was used to assess the influence of ginsenoside Rg3 and ZFP91 on tumor growth <i>in vivo</i>.<h4>Results</h4>Ginsenoside Rg3 reduced <i>ZFP9Journal of ginseng research636-645https://www.ebi.ac.uk/biostudies/studies/S-EPMC9459078biostudies-literatureGinsenoside Rg3 increases gemcitabine sensitivity of pancreatic adenocarcinoma via reducing ZFP91 mediated TSPYL2 destabilization.PMC9459078Pan HYang LLuo JBai HDeng YfalseGinsenoside Rg3 increases gemcitabine sensitivity of pancreatic adenocarcinoma via reducing ZFP91 mediated TSPYL2 destabilization.<h4>Background</h4>Ginsenoside Rg3 and gemcitabine have mutual enhancing antitumor effects. However, the underlying mechanisms are not clear. This study explored the influence of ginsenoside Rg3 on Zinc finger protein 91 homolog (ZFP91) expression in pancreatic adenocarcinoma (PAAD) and their regulatory mechanisms on gemcitabine sensitivity.<h4>Methods</h4>RNA-seq and survival data from The Cancer Genome Atlas (TCGA)-PAAD and Genotype-Tissue Expression (GTEx) were used for <i>in-silicon</i> analysis. PANC-1, BxPC-3, and PANC-1 gemcitabine-resistant (PANC-1/GR) cells were used for <i>in vitro</i> analysis. PANC-1 derived tumor xenograft nude mice model was used to assess the influence of ginsenoside Rg3 and ZFP91 on tumor growth <i>in vivo</i>.<h4>Results</h4>Ginsenoside Rg3 reduced <i>ZFP92022-01-01T00:00:00Z2022 Sep2026-07-14T17:33:46.709Z2025-04-20T00:38:58.453ZS-EPMC94590783609068110.1016/j.jgr.2021.08.004